Timothy Mills, Ph.D. Managing Director
Timothy Mills has over twenty-five years of experience in venture capital investing, corporate management, product development and biomedical research. Dr Mills has participated in 20+ companies in both investor and operating roles in the areas of: Biotherapeutics, Medical Technology and i-Health.
Dr. Mills joined Sanderling as an Operating Partner in July 1998, was promoted to Managing Director in 2000 and currently serves as the Chairman of the Investment Committee. His active roles within Sanderling’s portfolio companies include Chairman, CEO, Director, and management team member.
Portfolio companies previously served include; Stereotaxis (NASDAQ: STXS), Stentor, acquired by Royal Philips Electronics (NYSE: PHG, AEX: PHI), CardioNet (NASDAQ: BEAT), Taligen Therapeutics, acquired by Alexion Pharmaceuticals (NASDAQ: ALXN), Neomend, acquired by C.R. Bard (NYSE: BCR), Sotera Wireless, InfraReDx (acquired by Nipro Corporation), Pulsar Vascular, acquired by (NYSE: JNJ), Torax Medical, acquired by (NYSE: JNJ).
Prior to joining Sanderling, Dr. Mills served as the Corporate Vice President of New Business Development and Chief Scientific Officer of Target Therapeutics, a medical device company that was acquired by Boston Scientific (NYSE: BSX) in 1997 for $1.3 billion. From July 1994 to July 1997, he was a Director for Prograft Medical, a Target affiliate that was acquired by W.L Gore & Associates.
Before joining Target, Dr. Mills served as Director of Business Development and Advanced Research & Development in the Interventional Cardiology Division of Baxter Healthcare, now Edwards Life Science (NYSE: EW). Dr. Mills’ previous academic appointments included Director of the Artificial Heart Program at the University of California, Irvine Medical Center and faculty member at the University of California, San Francisco Radiology Department.
Dr. Mills received his Ph.D. in Bioengineering from the University of California, Berkeley & San Francisco School of Medicine. He also received a M.S. in Electrical Engineering & Computer Science from the University of California, Berkeley, and a B.S. in Electrical Engineering from the University of Colorado, Boulder. In addition, he is a Board of Director member of the University of Colorado’s University License Equity Holdings, Inc. (ULEHI) and a program faculty member of the Stanford University Biodesign and SPARK programs.